ANDA 78898, held by Zydus Pharms USA Inc. Galantamine Hydrobromide.
As of Nov 15, 2026, ANDA 78898 (Galantamine Hydrobromide), held by Zydus Pharms USA Inc, was first approved by FDA on Feb 17, 2011, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 17, 2011 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 4MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 8MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 12MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Oct 22, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 2, 2020 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 14, 2017 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 19, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 24, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 24, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 12, 2012 | Supplement 1Labeling | Approved | None posted |
| Feb 17, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters